Vascular Biogenics Stock Net Asset
| VBLTDelisted Stock | USD 0.28 0.01 3.45% |
Vascular Biogenics fundamentals help investors to digest information that contributes to Vascular Biogenics' financial success or failures. It also enables traders to predict the movement of Vascular Stock. The fundamental analysis module provides a way to measure Vascular Biogenics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vascular Biogenics stock.
Vascular |
Vascular Biogenics Company Net Asset Analysis
Vascular Biogenics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Vascular Biogenics Net Asset | 29.66 M |
Most of Vascular Biogenics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vascular Biogenics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Vascular Biogenics has a Net Asset of 29.66 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Vascular Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vascular Biogenics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vascular Biogenics could also be used in its relative valuation, which is a method of valuing Vascular Biogenics by comparing valuation metrics of similar companies.Vascular Biogenics is currently under evaluation in net asset category among its peers.
Vascular Fundamentals
| Return On Equity | -0.6 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (33.89) % | |||
| Current Valuation | (10.99 M) | |||
| Shares Outstanding | 77.64 M | |||
| Shares Owned By Insiders | 13.48 % | |||
| Shares Owned By Institutions | 14.00 % | |||
| Number Of Shares Shorted | 250.34 K | |||
| Price To Earning | (9.32) X | |||
| Price To Book | 0.35 X | |||
| Price To Sales | 9.63 X | |||
| Revenue | 658 K | |||
| Gross Profit | 554 K | |||
| EBITDA | (31.16 M) | |||
| Net Income | (32.3 M) | |||
| Cash And Equivalents | 34.15 M | |||
| Cash Per Share | 0.49 X | |||
| Total Debt | 564 K | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 4.05 X | |||
| Book Value Per Share | 0.27 X | |||
| Cash Flow From Operations | (31.59 M) | |||
| Short Ratio | 0.55 X | |||
| Earnings Per Share | (0.18) X | |||
| Target Price | 5.0 | |||
| Beta | 0.71 | |||
| Market Capitalization | 13.83 M | |||
| Total Asset | 29.66 M | |||
| Retained Earnings | (294.38 M) | |||
| Working Capital | 15.42 M | |||
| Current Asset | 38.59 M | |||
| Current Liabilities | 4.16 M | |||
| Z Score | -2.01 | |||
| Net Asset | 29.66 M |
About Vascular Biogenics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vascular Biogenics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vascular Biogenics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vascular Biogenics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Vascular Stock
If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |